Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
- 23 November 2013
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 121 (4) , 379-383
Abstract
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.Keywords
This publication has 18 references indexed in Scilit:
- Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?Current Topics in Medicinal Chemistry, 2012
- Type A and B Monoamine Oxidase in Age-Related Neurodegenerative Disorders: Their Distinct Roles in Neuronal Death and SurvivalCurrent Topics in Medicinal Chemistry, 2012
- From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitorsExpert Review of Clinical Pharmacology, 2012
- Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagilineMovement Disorders, 2011
- Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's DiseaseClinical Therapeutics, 2007
- Clinical Pharmacokinetics and Pharmacodynamics of SelegilineClinical Pharmacokinetics, 1997
- Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brainJournal of Neuroscience, 1992
- EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE A AND TYPE B MONOAMINE OXIDASE IN RAT BRAIN in vivo AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5‐HYDROXYTRYPTAMINEBritish Journal of Pharmacology, 1977
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal of Neural Transmission, 1975
- Multiple forms of human brain monoamine oxidase: substrate specificitiesBiochemical Journal, 1970